Prasad Adusumilli is a thoracic surgeon-scientist and Vice Chair of Translational Research in the Department of Surgery at Memorial Sloan Kettering Cancer Center, New York. Dr. Adusumilli's research laboratory comprising 20 to 25 members focuses on solid tumor immunology; his laboratory has analyzed tumors, peripheral blood, and body fluids from more than 12,000 patients. Using the knowledge generated from analyzing tumors from patients, supported by National Cancer Institute and Department of Defense awards, Dr. Adusumilli's laboratory established clinically relevant solid tumor models and investigated treatment with biological therapies, including oncolytic viruses and chimeric antigen receptor (CAR) T cells. Multiple clinical trials initiated by the Adusumilli laboratory have shown the safety and anticancer effects of CAR T cells. The resulting mechanistic data have been translated to clinical trials, including trials of combination immunotherapy to reactivate both CAR T-cell and endogenous immunity by use of cell-intrinsic and -extrinsic checkpoint blockade.